Taking a new approach: Therapeutic options for highly treatment-experienced HIV-1 patientsTheratechnologies Symposium Wednesday 27 October 2021, 16:15–17:15 BST 18th European AIDS Conference (EACS)

Join us for an exciting, expert-led symposium titled ‘Taking a new approach: Therapeutic options for highly treatment-experienced HIV-1 patients’.

Throughout this session we will explore the challenges of highly treatment-experienced patients with HIV-1, focusing on treatment and highlighting the pathophysiology and impact of reduced susceptibility on virological failure and rebound.

We will also consider the management of these patients from the virologist and pharmacologist perspectives, discussing both the mechanism of action and virologic characteristics of newly available treatments, and the impact of drug-drug interactions on creating effective optimised background regimens.

We look forward to welcoming you to this symposium.

This symposium is fully sponsored and supported by Theratechnologies Europe Limited, including speaker honoraria and production of materials, and may include promotional messages related to Theratechnologies products.

For more information, visit us at the Theratechnologies booth.

Taking a new approach: Therapeutic options for highly treatment-experienced HIV-1 patientsTIME PRESENTATION PRESENTER

16:15–16:20 Welcome and introductions Dr Graeme Moyle (Chair)Chelsea and Westminster Hospital, London, United Kingdom

16:20–16:35 Understanding the challenges of highly treatment-experienced HIV-1 patients

Prof. Antonella CastagnaSan Raffaele Hospital, Milan, Italy

16:35–16:50 A virologist’s perspective on management Prof. Anne-Geneviève MarcelinSorbonne University & Pitié-Salpêtrière Hospital, Paris, France

16:50–17:05 Building an optimised regimen: The impact of drug-drug interactions

Prof. David BackUniversity of Liverpool, Liverpool, United Kingdom

17:05–17:15 Discussion and Q&A All facultyQ&A facilitated by Dr Graeme Moyle (Chair)

This symposium is fully sponsored and supported by Theratechnologies Europe Limited, including speaker honoraria and production of materials, and may include promotional messages related to Theratechnologies products.

Prescribing information can be found here:

Price (TBD)

Ibalizumab SmPC

Date of prep: September 2021 |

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to +49 (0) 30 3119 6151 or medinfo.eu@theratech.com

Legal category: POMhttps://www.ema.europa.eu/en

UK-107-20211027-EACS-INSERT-EN-V02-00